Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 9, 2011, Pages 1348-1353

  Liu, Chen Hua ^a   Kao, Jia Horng ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN;

ASIAN; BODY MASS; CAUCASIAN; CHROMOSOME 19; DECOMPENSATED LIVER CIRRHOSIS; EDITORIAL; ETHNICITY; FATTY LIVER; FIBROSIS; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HISPANIC; HUMAN; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS LOAD;

EID: 80052353429     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06842.x     Document Type: Editorial

References (33)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N. Engl. J. Med. 2001; 345: 41-52.
2. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
3. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 975-82.
4. Hadziyannis SJ, Sette H Jr, Morgan TR etal. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004; 140: 346-55.
5. Yu ML, Dai CY, Huang JF etal. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884-93.
6. Liu CH, Liu CJ, Lin CL etal. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin. Infect. Dis. 2008; 47: 1260-9.
7. Liu CJ, Chuang WL, Lee CM etal. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009; 136: 496-504.e3.
8. Yu ML, Dai CY, Huang JF etal. A randomised study of peginterferon and ribavirin for 16 versus 24weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553-9.
9. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J. Gastroenterol. Hepatol. 2009; 24: 336-45.
10. Poordad F, McCone J Jr, Bacon BR etal. SPRINT-2 investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1195-206.
11. Jacobson IM, McHutchison JG, Dusheiko G etal. ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 364: 2405-16.
12. Bacon BR, Gordon SC, Lawitz E etal. HCV RESPOND-2 investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1207-17.
13. Zeuzem S, Andreone P, Pol S etal. REALIZE Study Team. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011; 364: 2417-28.
14. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J. Hepatol. 2011; 55: 69-75.
15. Moreno C, Deltenre P, Pawlotsky JM, Henrion J, Adler M, Mathurin P. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. J. Hepatol. 2010; 52: 25-31.
16. Farnik H, Lange CM, Sarrazin C, Kronenberger B, Zeuzem S, Herrmann E. Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection. Clin. Gastroenterol. Hepatol. 2010; 8: 884-90.
17. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
18. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009; 41: 1105-9.
19. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009; 41: 1100-4.
20. Rauch A, Kutalik Z, Descombes P etal. Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-45, 1345.e1-7.
21. Thomas DL, Thio CL, Martin MP etal. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
22. Thompson AJ, Muir AJ, Sulkowski MS etal. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-9.e18.
23. Hsu CS, Hsu SJ, Chen HC etal. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc. Natl. Acad. Sci. U. S. A. 2011; 108: 3719-24.
24. Mangia A, Thompson AJ, Santoro R etal. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-7. 827.e1.
25. Sarrazin C, Susser S, Doehring A etal. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J. Hepatol. 2011; 54: 415-21.
26. Yu ML, Huang CF, Huang JF etal. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011; 53: 7-13.
27. Moghaddam A, Melum E, Reinton N etal. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011; 53: 746-54.
28. Stättermayer AF, Stauber R, Hofer H etal. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin. Gastroenterol. Hepatol. 2011; 9: 344-50.e2.
29. Lindh M, Lagging M, Färkkilä M etal. Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J. Infect. Dis. 2011; 203: 1748-52.
30. Lin CY, Chen JY, Lin TN etal. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS ONE 2011; 6: e18322.
31. Ochi H, Maekawa T, Abe H etal. IL-28B predicts response to chronic hepatitis C therapy-fine-mapping and replication study in Asian populations. J. Gen. Virol. 2011; 92: 1071-81.
32. Liao XW, Ling Y, Li XH etal. Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. Antivir. Ther. 2011; 16: 141-7.
33. Sinn DH, Kim YJ, Lee ST etal. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients. J. Gastroenterol. Hepatol. 2011; 26: 1374-9.